-
摘要: 目的：探讨沉默调节蛋白1（SIRT1）在膀胱癌组织中的表达情况及在肿瘤进展、侵袭、转移中的作用。方法：选取82例不同病理分期的膀胱尿路上皮癌患者术后石蜡标本，采用免疫组织化学技术检测癌组织及癌旁正常组织中SIRT1的表达，分析其与临床病理特征的关系。另选取15例膀胱尿路上皮癌行膀胱根治术患者的癌组织和癌旁组织，应用Real-Time PCR技术检测SIRT1 mRNA表达水平。结果：SIRT1的表达水平与临床分期、病理分级及是否转移呈相关性（P<0.05），与性别、年龄、是否复发无相关性（P>0.05）。癌组织中SIRT1 mRNA的表达明显高于癌旁组织的表达，差异有统计学意义（P<0.05）。结论：SIRT1在膀胱癌组织呈高表达，与临床分期及转移相关，有可能作为肿瘤进展的潜在标志物及治疗靶点。Abstract: Objective: To investigate the expression of SIRT1 in bladder urothelial carcinoma and its possible role in the occurrence, progression, invasion and metastasis of bladder urinary epithelial cell carcinoma. Method: The expression of SIRT1 was detected by immunohistochemistry in the paraffin sections of 82 patients with different pathological stages of bladder urothelial carcinoma after operation. The correlation between the expression of SIRT1 and clinical pathological characters was explored. SIRT1 mRNA levels in bladder urothelial carcinoma tissues and those adjacent to carcinoma tissues were analyzed by real-time PCR respectively. Result: The expression of SIRT1 was positively correlated with pathological grade, clinical stage and metastasis, but not related with sex, age,recurrence. The relative expression of SIRT1 mRNA levels in bladder urothelial carcinoma was significantly higher than that in para cancerous tissues.Conclusion: The expression of SIRT1 showed much higher in bladder urothelial carcinoma, and it's related to clinical stages and metastasis. It can probably provide an ideal biomarker for tumor progression and target for therapy of urothelial carcinoma.
-
Key words:
- bladder cancer /
- SIRT1 /
- clinical stage /
- metastasis
-
-
[1] 黄传书, 蒋国松, 黄超.膀胱癌治疗基础及临床转化研究的前沿和热点[J].临床泌尿外科杂志, 2017, 32(10):735-740.
[2] DeSantis C E, Lin C C, Mariotto A B, et al.Cancer treatment and survivorship statistics[J].CA Cancer J Clin, 2014, 64(4):252-271.
[3] 陈万青, 郑荣寿, 张思维, 等.2013年中国老年人群恶性肿瘤发病和死亡分析[J].中华肿瘤杂志, 2017, 39(2):60-66.
[4] Della-Morte D, Ricordi C, Rundek T.The fountain of youth:role of sirtuins in aging and regenerative medicine[J].Regen Med, 2013, 8(6):681-683.
[5] Yang H, Bi Y, Xue L, et al.Multifaceted modulation of SIRT 1 in cancer and inflammation[J].Crit Rev Oncog, 2015, 20(12):49-64.
[6] Wang Q, Yan C, Xin M, et al.Sirtuin 1(Sirt1) Overexpression in BaF3 Cells Contributes to Cell Proliferation Promotion, Apoptosis Resistance and Pro-Inflammatory Cytokine Production[J].Med Sci Monit, 2017, 23:1477-1482.
[7] Suzuki M, Bartlett J D.Sirtuinl and autophagy protect cells from fluoride-induced cell stress[J].Biochim Biophys Acta, 2014, 1842(2):245-255.
[8] Yi J, Luo J.SIRT1 and p53, effect on cancer, senescence and beyond[J].Biochim Biophys Acta, 2010, 1804(8):1684-1689.
[9] 刘正升, 陈磊, 邢金春.膀胱癌新型基因和生物标记物研究进展[J].临床泌尿外科杂志, 2017, 32(2):157-160.
[10] 蓝宇, 刘东东, 林明恩, 等.沉默信息调节因子1在膀胱尿路上皮癌中的表达与意义[J].癌症畸变突变, 2015, 27(2):125-128.
[11] Byles V, Zhu L, Lovaas J D, et al.SIRT1 induces EMT by cooperating with EMT transcription factors and enhances prostate cancer cell migration and metastasis[J].Oncogene, 2012, 31(43):4619-4629.
[12] Hao C, Zhu P X, Yang X, et al.Overexpression of SIRT1 promotes metastasis through epithelial-mesenchymal transition in hepatocellular carcinoma[J].BMC Cancer, 2014, 14:978.
[13] Palmirotta R, Cives M, Della-Morte D, et al.Sirtuins and Cancer:Role in the Epithelial-Mesenchymal Transition[J].Oxid Med Cell Longev, 2016, 2016:3031459.
[14] Yuan J, Minter-Dykhouse K, Lou Z.Ac-Myc-SIRT1 feedback loop regulates cell growth and transformation[J].J Cell Biol, 2009, 185(2):203-211.
[15] Li J, Dong G, Wang B, et al.MiR-543 promotes gastric cancer cell proliferation by targeting SIRT1[J].Biochem Biophys Res Commun, 2016, 469(1):15-21.
[16] Zhang L, Wang X, Chen P, et al.MiR-204 down regulates SIRT1 and reverts SIRT1-induced epithelial-mesenchymal transition, anoikis resistance and invasion in gastric cancer cells[J].BMC Cancer, 2013, 13:290-298.
-
计量
- 文章访问数: 298
- PDF下载数: 524
- 施引文献: 0
下载: